← Eichor
Study identifier: NCT06801522 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Adrenaline Nasal Pack vs Xylometazoline Nasal Drops During Nasotracheal Intubation

Condition: Nasal Bleeding · Nasotracheal Intubation  ·  Sponsor: Shaheed Mohtarma Benazir Bhutto Institue of Trauma

PhasePhase 2/Phase 3
Planned participants70
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

The goal of this trial is to compare efficacy of xylometazoline nasal drops and adrenaline nasal pack in participants undergoing elective oromaxillofacial surgeries. The main question aim to answer is xylometazoline nasal drops better than adrenaline nasal packing in terms of nasal bleeding during nasotracheal intubation. Researchers are comparing 2 groups of participants. Participants in group Xylometazoline are receiving 0.1% xylometaxoline nasal drops. Participants in group Adrenaline are receiving adrenaline nasal packing.

This description comes directly from the study's public registry record.

Talk to the study team

Dr Sidra Javed Consultant Anaesthetist, MBBS, FCPS, PAIN FELLOW  ·  +92333 2474831  ·  sidra_dow@yahoo.com

Dr Mirza Shahzad Baig Consultant Anaesthetist, MBBS, MCPS, FCPS  ·  +923346441539  ·  drshahzadbaig@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shaheed Mohtarma Benazir Bhutto Institute of TraumaKarachi, Sindh, PakistanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06801522